Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Genentech
Hemlibra
Другие языки:

    Hemlibra

    Подписчиков: 0, рейтинг: 0

    Emicizumab
    Monoclonal antibody
    Type Whole antibody
    Source Humanized
    Target Activated factor IX, factor X
    Clinical data
    Trade names Hemlibra
    Other names ACE910, emicizumab-kxwh
    AHFS/Drugs.com Monograph
    License data
    Pregnancy
    category
    • AU: B2
    Routes of
    administration    		 Subcutaneous
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • CA: Rx-only / Schedule D
    • US: ℞-only
    • EU: Rx-only
    • In general: ℞ (Prescription only)
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    Chemical and physical data
    Formula C6434H9940N1724O2047S45
    Molar mass 145639.02 g·mol−1

    Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Hoffmann-La Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects.

    In November 2017, it was approved in the United States for treatment of haemophilia A in those who had developed resistance to other treatments. It was subsequently approved by the US FDA in April 2018 under the breakthrough therapy designation for treatment of haemophila A in those who have not developed resistance to other treatments. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

    Mechanism of action

    Emicizumab binds to both the activated coagulation factor IX and to factor X, mediating the activation of the latter. This is normally the function of coagulation factor VIII, which is missing in haemophilia A patients.

    See also

    External links

    • "Emicizumab". Drug Information Portal. U.S. National Library of Medicine.



    Новое сообщение